tbuckley/cabot-search huggingface dataset:
Patient-level meta-analysis of randomized trials of aromatase inhibitors (AI) versus tamoxifen (Tam).
Authors: John F. Forbes, Mitchell Dowsett, Rosie Bradley, James N. Ingle, Tomohiko Aihara, Judith M. Bliss, Francesco Mario Boccardo, Alan S. Coates, R. Charles Coombes, Jack M. Cuzick, Peter Christian Dubsky, Michael Gnant, Manfred Kaufmann, Lucy S Kilburn, Francesco Perrone, Daniel Rea, Beat J. K. Thurlimann, Cornelis J. H. Van De Velde, Christina Davies, Richard G. Gray
Journal: Journal of Clinical Oncology (2014)

529 Background: The optimal way to schedule AIs and/or Tam in the adjuvant treatment of early breast cancer remains uncertain. Methods: ITT meta-analysis of individual patient data on 36 889 post-menopausal women with ER-positive invasive breast cancers in randomised trials of [A] Continuous AI (5yrs) vs Tam (5yrs); [B] Sequential Tam then AI (2-3yrs of Tam then 2-3 yrs AI) vs Tam (5yrs); [C] Continuous AI (5yrs) vs Sequential Tam then AI (5yrs). Results: [A] Fewer women had breast cancer recurrence with Continuous AI than Tam (827/4,970 vs 964/4,915, p<0.0001) and fewer died of breast cancer: 504 vs 562; rate ratio (RR) 0.86 [0.76-0.97], p=0.014. Recurrence RRs were: 0.66 during yrs 0-1 [95%CI 0.54-0.80], 0.75 during yrs 2-4 [0.64-0.88] and 0.90 in yrs 5+ [0.79-1.04]. [B] Recurrence was also lower with Sequential Tam then AI than with Tam alone (753/5,909 vs 863/5,889, p=0.0001) as was breast cancer mortality (361 vs 428 deaths; RR 0.84 [0.73-0.97], p=0.015). Recurrence RRs were 0.56 during yrs 2-4 [0.46-0.67] and 0.97 in yrs 5+ [0.86-1.09]. [C] In trials comparing Continuous AI versus Sequential Tam then AI, recurrence was lower with AI than Tam during yrs 0-1; RR 0.75 [0.62-0.89], but similar during yrs 2-4 (0.99 [0.85-1.15]), when both groups received AI, and in yrs 5+ (0.96 [0.76-1.21]) after treatment completion; overall, there were fewer recurrences with Continuous AI than Sequential Tam then AI (705/6,422 vs 764/6,377, RR 0.90 [0.81-1.00]; 5yr recurrence 9.6% vs 10.7%, p=0.042) and fewer breast cancer deaths (395 vs 432; 0.89 [0.77-1.02], p=0.097). In the 3 comparisons, proportional recurrence reductions did not differ much by age, nodal status, tumour grade, or PR status and, overall, fewer endometrial cancers (0.2% vs 0.6%, RR=0.37 [0.27-0.51]) but more fractures (8.1% vs 5.9%, RR=1.40 [1.27-1.53]) were seen with AIs than Tam; non-breast deaths were similar. Conclusions: AIs, in either Continuous or Sequential regimens, are even more effective than Tam monotherapy in preventing recurrence and breast cancer death, despite substantial cross-over from Tam to AI in some studies. Recurrence reductions are seen mainly while treatments differ, hence somewhat fewer recurrences with Continuous AI than Sequential Tam then AI.
Abstract 12776: Long Term Mortality With Right Ventricular Apical Versus Septal Pacing
Authors: Chance M Witt, Charles J Lenz, Henry H Shih, Elisa Ebrille, Andrew N Rosenbaum, Htin Aung, Martin van Zyl, Kevin K Manocha, Abhishek J Deshmukh, David O Hodge, Samuel J Asirvatham, Christopher J McLeod
Journal: Circulation (2015)

Introduction: Right ventricular apical (RVA) pacing appears to have detrimental effects on cardiac function and long term outcomes. Right ventricular non-apical (RVNA) pacing, especially in the septal position, has been postulated as an alternative that may lead to less morbidity and mortality. Prior studies have shown conflicting results and been limited by small numbers and short follow-up. We aimed to determine if right ventricular septal lead position was associated with a reduction in long-term mortality compared to RVA lead position. Methods: Patients who underwent dual-chamber pacemaker implantation from 2004 through 2013 were evaluated for right ventricular lead position based on chest radiographs. Lead positions were divided in to apical or non-apical. Non-apical lead positions were subdivided to isolate a septal lead position group. Mortality was compared between these groups. Results: During the study period, 3456 patients underwent dual-chamber pacemaker placement and had images appropriate for lead position evaluation. The group was 53.5% male with a mean age of 74 ± 13 years. RVNA lead position was found in 976 (28.2%) patients, including 243 (7.0%) with a septal position. There was no significant difference in age or prior heart failure diagnosis between groups. Kaplan-Meier survival analysis did not reveal a significant difference in mortality between patients with RVA versus RVNA lead position during 5 year follow-up (p = 0.82). However, septal lead position was associated with a significantly lower mortality compared with RVA position (p = 0.03) (figure). Conclusions: Right ventricular septal lead position is associated with a lower long-term mortality than RVA lead position. This has substantial implications regarding the preferred site for ventricular pacing lead placement.
Cardiovascular Health Promotion in Children: Challenges and Opportunities for 2020 and Beyond: A Scientific Statement From the American Heart Association
Authors: Julia Steinberger, Stephen R. Daniels, Nancy Hagberg, Carmen R. Isasi, Aaron S. Kelly, Donald Lloyd-Jones, Russell R. Pate, Charlotte Pratt, Christina M. Shay, Jeffrey A. Towbin, Elaine Urbina, Linda V. Van Horn, Justin P. Zachariah
Journal: Circulation (2016)

This document provides a pediatric-focused companion to “Defining and Setting National Goals for Cardiovascular Health Promotion and Disease Reduction: The American Heart Association’s Strategic Impact Goal Through 2020 and Beyond,” focused on cardiovascular health promotion and disease reduction in adults and children. The principles detailed in the document reflect the American Heart Association’s new dynamic and proactive goal to promote cardiovascular health throughout the life course. The primary focus is on adult cardiovascular health and disease prevention, but critical to achievement of this goal is maintenance of ideal cardiovascular health from birth through childhood to young adulthood and beyond. Emphasis is placed on the fundamental principles and metrics that define cardiovascular health in children for the clinical or research setting, and a balanced and critical appraisal of the strengths and weaknesses of the cardiovascular health construct in children and adolescents is provided. Specifically, this document discusses 2 important factors: the promotion of ideal cardiovascular health in all children and the improvement of cardiovascular health metric scores in children currently classified as having poor or intermediate cardiovascular health. Other topics include the current status of cardiovascular health in US children, opportunities for the refinement of health metrics, improvement of health metric scores, and possibilities for promoting ideal cardiovascular health. Importantly, concerns about the suitability of using single thresholds to identify elevated cardiovascular risk throughout the childhood years and the limits of our current knowledge are noted, and suggestions for future directions and research are provided.
Review of<i>Medication-Induced Movement Disorders</i>
Authors: Neepa Patel
Journal: JAMA Neurology (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Neurology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Neurology journal
Bioabsorbable Intracoronary Matrix for Prevention of Ventricular Remodeling After Myocardial Infarction
Authors: Sunil V. Rao, Uwe Zeymer, Pamela S. Douglas, Hussein Al-Khalidi, Jennifer A. White, Jingyu Liu, Howard Levy, Victor Guetta, C. Michael Gibson, Jean-Francois Tanguay, Paul Vermeersch, Jérôme Roncalli, Jaroslaw D. Kasprzak, Timothy D. Henry, Norbert Frey, Oscar Kracoff, Jay H. Traverse, Derek P. Chew, Jose Lopez-Sendon, Reinilde Heyrman, Mitchell W. Krucoff
Journal: Journal of the American College of Cardiology (2016)
Red Blood Cell Transfusion Strategies and Health Care–Associated Infection—Reply
Authors: Mary A. M. Rogers
Journal: JAMA (2014)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
A phase IIa study of ABT-263 in patients with relapsed small-cell lung cancer (SCLC).
Authors: C. M. Rudin, M. R. Oliveira, E. B. Garon, P. Bonomi, D. R. Camidge, C. Nolan, T. Busman, A. Krivoshik, R. Humerickhouse, L. Gandhi
Journal: Journal of Clinical Oncology (2010)

7046 Background: ABT-263, a novel BH3 mimetic, binds with high affinity (Ki ≤ 1 nM) and inhibits multiple antiapoptotic Bcl-2 proteins. SCLC is an aggressive cancer, which constitutes nearly 15% of all lung neoplasms in the United States and has few effective treatment options after first-line therapy. SCLC tumors frequently overexpress Bcl-2. Results from a phase I trial showed that single-agent ABT-263 was well tolerated and had activity in previously treated patients (pts) with SCLC and other neuroendocrine carcinomas. Methods: This is an open-label, multicenter phase IIa trial assessing safety and preliminary efficacy of ABT-263 in pts with extensive-stage SCLC. ABT-263 was dosed orally at 325 mg once daily, following a 7-day lead-in dose of 150 mg, on a 21-day cycle until progressive disease (PD) or intolerable toxicity. Key eligibility criteria included measurable SCLC and ECOG status ≤ 1. Endpoints include tumor response by RECIST, progression-free survival, time to progression, overall survival, and ECOG performance status. Tumor assessments were performed at the end of every 2 cycles. Adverse events (AE) were graded by NCI CTCAE V3. Results: 39 pts were enrolled from 06/09 to 12/09; 21 discontinued due to PD and 4 withdrew consent. 14 remain on study (4 with stable disease). Median time on study was 49 days (35, NA). 6 pts had dose reductions due to AEs and 11 had serious AE (SAE, Table). The most common AEs were diarrhea (43%), back pain (43%), and thrombocytopenia (TCP; 29%). The most common grade 3/4 AE was TCP (29%). 4 pts had dose interruptions due to AEs. Conclusions: Preliminary results from this phase II study show that ABT-263 has an acceptable safety profile. SCLC antitumor activity was noted in the phase I portion of the study and the evaluation of tumor response is ongoing in the phase II portion. Updated results of this ongoing study will be presented. Patients SAE 401 Obstruction right mainstem bronchus Metastatic SCLC 402 Neutropenic fever Dehydration Hypotension 406 Shortness of breath 407 Bone metastasis PD 410 Death 411 Neutropenic fever 413 Volume depletion Vomiting-dehydration 414 Pneumonia 417 Hyponatremia Constipation 428 PD 429 Pleural effusion Anemia Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Abbott Laboratories Abbott Laboratories, Myriad Genetics Abbott Laboratories Abbott Laboratories, Genentech
A Phase 1/2 Study Of KW-2478, An Hsp 90 Inhibitor, In Combination With Bortezomib (BTZ) In Patients (Pts) With Relapsed/Refractory (R/R) Multiple Myeloma (MM)
Authors: Cavanagh Jamie, Honorata Giongco Baylon, Priscilla B. Caguioa, Faith E. Davies, Mecide Gharibo, Shiro Akinaga, Michael R. Kurman, Barbara A. Novak, Kwee L. Yong
Journal: Blood (2013)
Preliminary Results of a Phase I Study of Nivolumab (BMS-936558) in Patients with Relapsed or Refractory Lymphoid Malignancies
Authors: Alexander M. Lesokhin, Stephen M. Ansell, Philippe Armand, Emma C. Scott, Ahmad Halwani, Martin Gutierrez, Michael M. Millenson, Adam D. Cohen, Stephen J. Schuster, Daniel Lebovic, Madhav V. Dhodapkar, David Avigan, Bjoern Chapuy, Azra H. Ligon, Scott J. Rodig, Deepika Cattry, Lili Zhu, Joseph F. Grosso, Su Young Kim, Margaret A. Shipp, Ivan Borrello, John Timmerman
Journal: Blood (2014)
N-linked glycans within the A2 domain of von Willebrand factor modulate macrophage-mediated clearance
Authors: Alain Chion, Jamie M. O’Sullivan, Clive Drakeford, Gudmundur Bergsson, Niall Dalton, Sonia Aguila, Soracha Ward, Padraic G. Fallon, Teresa M. Brophy, Roger J. S. Preston, Lauren Brady, Orla Sheils, Michael Laffan, Thomas A. J. McKinnon, James S. O’Donnell
Journal: Blood (2016)
Maternal extracellular vesicles and platelets promote preeclampsia via inflammasome activation in trophoblasts
Authors: Shrey Kohli, Satish Ranjan, Juliane Hoffmann, Muhammed Kashif, Evelyn A. Daniel, Moh'd Mohanad Al-Dabet, Fabian Bock, Sumra Nazir, Hanna Huebner, Peter R. Mertens, Klaus-Dieter Fischer, Ana C. Zenclussen, Stefan Offermanns, Anat Aharon, Benjamin Brenner, Khurrum Shahzad, Matthias Ruebner, Berend Isermann
Journal: Blood (2016)
Diagnostic testing in primary ciliary dyskinesia
Authors: Israel Amirav, Patrick M. Boussuyt
Journal: European Respiratory Journal (2016)

The primary ciliary dyskinesia (PCD) group in Southampton, UK, led by J.S. Lucas is to be applauded for its recent efforts to improve the accuracy of PCD diagnosis. In two recent articles published by the group in the European Respiratory Journal [1, 2], a large number of PCD referral cases were analysed and various conclusions were drawn regarding diagnostic accuracy, as well as derivation of a clinical prediction rule that was suggested to aid in further referral and investigations for PCD. Until we have better reference tests for PCD, diagnostic accuracy cannot be meaningfully evaluated or claimed <http://ow.ly/4n6VrI>
General Internal Medicine
Authors: J R Feussner, D L Simel
Journal: JAMA (1993)

With the increasing demand for and cost of medical care, policymakers recognize the need to reconsider the organization of health care in the United States. Any reordering of health care priorities will focus on providing optimum care at minimum cost and can only advance the role of general internal medicine. During the past year, research relevant to general internal medicine focused on several issues: (1) more cost-effective approaches to diagnosis and treatment of common clinical problems using low-technology approaches that include the clinical history and physical examination; (2) the role of gender in medical care, focusing on women as physicians, patients, and subjects in research studies; and (3) internal medicine manpower overall and general internal medicine specifically. Multiple research reports have documented the utility of routine clinical observations for establishing diagnoses and targeting therapies for common clinical problems.<i>JAMA</i>has even begun a new series of articles called the "Rational
Senate Committee Holds Hearing on Palliative and Hospice Care
Authors: Rita Rubin
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
T Cell Factor 1-Expressing Memory-like CD8+ T Cells Sustain the Immune Response to Chronic Viral Infections
Authors: Daniel T. Utzschneider, Mélanie Charmoy, Vijaykumar Chennupati, Laurène Pousse, Daniela Pais Ferreira, Sandra Calderon-Copete, Maxime Danilo, Francesca Alfei, Maike Hofmann, Dominik Wieland, Sylvain Pradervand, Robert Thimme, Dietmar Zehn, Werner Held
Journal: Immunity (2016)
The Dark Matter of Cerebral Microbleeds
Authors: Andreas Charidimou
Journal: JAMA Neurology (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Neurology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Neurology journal
Gefitinib-induced cell death in short term fresh tumor cultures predicts for long term patient survival in previously-treated non-small cell lung cancer
Authors: L. Weisenthal
Journal: Journal of Clinical Oncology (2006)

17117 Background: Gefitinib (GEF) may act by inhibiting anti-apoptotic signals transduced by mutant EGFR kinase (Science 305:1163,04). Cell culture assays with cell death endpoints could be informative for GEF activity. Methods: We tested 568 biopsies of fresh human tumors (TUM) with 2 concentrations of GEF (22 and 11 μg/ml) for 96 hrs, each with 2 separate cell death endpoints (DISC and MTT), detailed methods http://weisenthal.org/w_ovarian_cp.pdf . Results classified as resistant (RES), intermediate (INT), or sensitive (SEN) based on means and standard deviations of training set data (ref ibid), reported prospectively to 3 different physicians: surgeon, pathologist, and oncologist. Assay evaluability rate &gt; 90%. Results: Based on overall % control cell death, the following TUM showed (on average) no greater RES or SEN than the universe of 568 assays: NSCLC (n = 72), colon (33), breast (106), ovarian (109), melanoma (23), pancreatic (20), endometrial (12). The following showed (on avg) significantly greater RES: soft tissue sarcomas (n = 24), carcinoid/islet (16), renal (15), and mesothelioma (8). For NSCLC, there was no avg difference between female (32) vs male (35) or untreated (34) vs previously treated (38). For 32 unRxd pts with survival data, there was no significant difference in overall surv for 20 pts with prospectively reported GEF RES (GR) assays vs 12 pts with SEN or INT (GSI) assays. For 31 pts with prior chemoRx (med surv = 155 days), there was significant survival disadvantage for 14 pts with prospectively reported GR vs 17 pts with GSI (median 85 vs 380 days, P2 &lt; 0.0001, HR 3.7; 95% C.I. 2.6–19). For pts with known post-assay Rx, there were 7 pts with GSI subsequently receiving GEF or erlotinib (ERLOT), with med surv = 485 days; 9 pts with GSI not receiving GEF or ERLOT, med surv = 135 days; 10 pts with GR not receiving GEF or ERLOT, med surv = 76 days, and 3 pts with GR receiving GEF or ERLOT, med surv = 75 days. Survival of group of 7 pts was significantly greater than those of groups of 9, 10, and 3 pts (P2 = 0.02, P2 &lt; 0.0001, and P2 = 0.002, respectively). Conclusions: GEF-induced cell death in cultures of fresh TUM from prev-treated NSCLC pts may identify pts with favorable prognosis, particularly when treated with GEF or ERLOT. [Table: see text]
In-Vivo Activation Of STAT3 In Angioimmunoblastic T Cell Lymphoma, PTCL Not Otherwise Specified, and ALK Negative Anaplastic Large Cell Lymphoma: Implications For Therapy
Authors: Mamta Gupta, Matthew J. Maurer, Mary Stenson, Linda E. Wellik, Jing Jing Han, Andrew L. Feldman, Thomas M. Habermann, Thomas E. Witzig
Journal: Blood (2013)
The epidemiology and transmissibility of Zika virus in Girardot and San Andres island, Colombia, September 2015 to January 2016
Authors: Diana Patricia Rojas, Natalie E Dean, Yang Yang, Eben Kenah, Juliana Quintero, Simon Tomasi, Erika Lorena Ramirez, Yendi Kelly, Carolina Castro, Gabriel Carrasquilla, M Elizabeth Halloran, Ira M Longini
Journal: Eurosurveillance (2016)

Transmission of Zika virus (ZIKV) was first detected in Colombia in September 2015. As of April 2016, Colombia had reported over 65,000 cases of Zika virus disease (ZVD). We analysed daily surveillance data of ZVD cases reported to the health authorities of San Andres and Girardot, Colombia, between September 2015 and January 2016. ZVD was laboratory-confirmed by reverse transcription-polymerase chain reaction (RT-PCR) in the serum of acute cases within five days of symptom onset. We use daily incidence data to estimate the basic reproductive number (R0) in each population. We identified 928 and 1,936 reported ZVD cases from San Andres and Girardot, respectively. The overall attack rate for reported ZVD was 12.13 cases per 1,000 residents of San Andres and 18.43 cases per 1,000 residents of Girardot. Attack rates were significantly higher in females in both municipalities (p < 0.001). Cases occurred in all age groups with highest rates in 20 to 49 year-olds. The estimated R0 for the Zika outbreak was 1.41 (95% confidence interval (CI): 1.15-1.74) in San Andres and 4.61 (95% CI: 4.11-5.16) in Girardot. Transmission of ZIKV is ongoing in the Americas. The estimated R0 from Colombia supports the observed rapid spread.